Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GLIS family zinc finger 3 (GLIS3) is a Krüppel-like zinc finger transcription factor containing five C2H2-type zinc finger domains. GLIS3 acts as both a repressor and activator of gene transcription by binding to specific DNA sequences. It plays critical roles during embryonic development, particularly in the pancreas, thyroid, eye, liver, and kidney. Mutations in GLIS3 lead to neonatal diabetes and congenital hypothyroidism, with additional associations to other syndromic features such as polycystic kidney disease and facial abnormalities. The protein regulates cell specification and the expression of key hormones and transcription factors, notably controlling insulin gene expression in pancreatic beta cells. No approved drugs directly target GLIS3, but its genetic variants serve as important biomarkers for certain monogenic diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GLIS family zinc finger 3 (GLIS3).